Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Aoki KR. Editorial comment on ‘5 year experience with incobotulinumtoxinA (Xeomin ® ) the first botulinum toxin drug free of complexing proteins’. Eur J Neurol 2011;19:355-6. [DOI: 10.1111/j.1468-1331.2011.03560.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]

For:	Aoki KR. Editorial comment on ‘5 year experience with incobotulinumtoxinA (Xeomin ® ) the first botulinum toxin drug free of complexing proteins’. Eur J Neurol 2011;19:355-6. [DOI: 10.1111/j.1468-1331.2011.03560.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]

Number

Cited by Other Article(s)

Kamm C, Schümann F, Mix E, Benecke R. Secondary antibody-induced treatment failure under therapy with incobotulinumtoxinA (Xeomin®) in a patient with segmental dystonia pretreated with abobotulinumtoxinA (Dysport®). J Neurol Sci 2015;350:110-1. [PMID: 25656102 DOI: 10.1016/j.jns.2015.01.032] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2014] [Revised: 01/21/2015] [Accepted: 01/22/2015] [Indexed: 11/26/2022]

Schapira AHV. Progress in European neurology 2012-2013. Eur J Neurol 2014;20:1499-507. [PMID: 24433475 DOI: 10.1111/ene.12303] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]